XOMA Royalty reports Q4/FY2024 revenue $28.5M, net loss $13.8M; portfolio doubled to 120+ assets

XOMA Royalty Corp

Total revenue $8.7M Q4, $28.5M FY2024 (vs $1.8M and $4.8M in 2023); net loss $4.0M Q4, $13.8M FY2024.
Cash and equivalents $106.4M at Dec 31, 2024; cash receipts totaled $46.3M in FY2024.
Doubled royalty portfolio to over 120 assets via five 2024 transactions: Twist ($15M), Daré ($22M), Talphera ($8M), Kinnate ($2.5879/sh + CVR), Pulmokine ($20M).
FDA approvals for Day One's OJEMDA and Zevra's MIPLYFFA; milestone payments received from both.
Non-cash credit losses $30.9M FY2024 (Agenus, Aronora, Talphera); management sees path to cash flow positive from royalties alone in 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.